We highlight how GLP-1 and estrogen are thought to have synergistic effects and summarize recent work on the use of GLP-1 conjugates as agents to manage obesity, T2D and central insulin resistance. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.